Background: Type 1 narcolepsy is a neurological disorder characterized by excessive daytime sleepiness and cataplexy associated with the HLA allele DQB1*06:02. Genetic predisposition along with external triggering factors may drive autoimmune responses, ultimately leading to the selective loss of hypocretin-positive neurons.
Objective: The aim of this study was to investigate potential aetiological factors in Swedish cases of postvaccination (Pandemrix) narcolepsy defined by interferon-gamma (IFNγ) production from immune cells in response to molecularly defined targets.
Methods: Cellular reactivity defined by IFNγ production was examined in blood from 38 (HLA-DQB1*06:02(+) ) Pandemrix-vaccinated narcolepsy cases and 76 (23 HLA-DQB1*06:02(+) and 53 HLA-DQB1*06:02(-) ) control subjects, matched for age, sex and exposure, using a variety of different antigens: β-haemolytic group A streptococcal (GAS) antigens (M5, M6 and streptodornase B), influenza (the pandemic A/H1N1/California/7/09 NYMC X-179A and A/H1N1/California/7/09 NYMC X-181 vaccine antigens, previous Flu-A and -B vaccine targets, A/H1N1/Brisbane/59/2007, A/H1N1/Solomon Islands/3/2006, A/H3N2/Uruguay/716/2007, A/H3N2/Wisconsin/67/2005, A/H5N1/Vietnam/1203/2004 and B/Malaysia/2506/2004), noninfluenza viral targets (CMVpp65, EBNA-1 and EBNA-3) and auto-antigens (hypocretin peptide, Tribbles homolog 2 peptide cocktail and extract from rat hypothalamus tissue).
Results: IFN-γ production was significantly increased in whole blood from narcolepsy cases in response to streptococcus serotype M6 (P = 0.0065) and streptodornase B protein (P = 0.0050). T-cell recognition of M6 and streptodornase B was confirmed at the single-cell level by intracellular cytokine (IL-2, IFNγ, tumour necrosis factor-alpha and IL-17) production after stimulation with synthetic M6 or streptodornase B peptides. Significantly, higher (P = 0.02) titres of serum antistreptolysin O were observed in narcolepsy cases, compared to vaccinated controls.
Conclusion: β-haemolytic GAS may be involved in triggering autoimmune responses in patients who developed narcolepsy symptoms after vaccination with Pandemrix in Sweden, characterized by a Streptococcus pyogenes M-type-specific IFN-γ cellular immune response.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/joim.12355 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Background: Narcolepsy is a chronic disorder that requires lifelong management; however, few studies have evaluated disease burden of narcolepsy. We estimated the healthcare burden of narcolepsy in Japan using data from the Japan Medical Data Center health insurance claims database.
Methods: This was a retrospective analysis of clinical burden, healthcare resource utilization, and costs among incident narcolepsy cases and matched controls identified between January 1, 2014 and December 31, 2019.
First Episode Psychosis in a Teen with Narcolepsy and Cataplexy.
Psychopharmacol Bull
January 2025
Abhishek Reddy, MD, Assistant Professor, Child and Adolescent Psychiatry, Sleep Medicine, Department of Psychiatry, Virginia Tech Carilion School of Medicine, Roanoke, VA, United States.
Article Synopsis
- Narcolepsy with cataplexy (NT1) is a rare sleep disorder that can be linked to early-onset psychosis, particularly in kids and teens.
- After excluding other medical issues, an adolescent girl with NT1 was initially diagnosed with a brief psychotic episode and treated with Risperidone.
- Her symptoms improved significantly after switching to Chlorpromazine, marking one of the first successful uses of this drug for managing first-episode psychosis in a patient with NT1.
Corticosteroid-responsive narcolepsy type II after COVID-19: A relevant differential diagnosis of post-COVID syndrome (a case report).
J Sleep Res
December 2024
Department of Neurology, Jena University Hospital, Jena, Germany.
Article Synopsis
- Excessive daytime sleepiness can be a symptom of post-COVID syndrome and narcolepsy, a rare sleep disorder that may have an autoimmune cause.
- A case study of a 25-year-old male showed he developed narcolepsy type II after COVID-19, confirmed through sleep tests and neuropsychological evaluations.
- Treatment with high-dose corticosteroids led to an immediate improvement in his symptoms, suggesting that immunosuppressive therapy might be a viable option for managing narcolepsy following COVID-19.
Epidemiology of narcolepsy and idiopathic hypersomnia in Japan: A retrospective analysis of health insurance claims from the Japan Medical Data Center.
Sleep Med
February 2025
Takeda Development Center Americas, Inc., Cambridge, MA, USA.
Article Synopsis
- Estimation of narcolepsy and idiopathic hypersomnia (IH) prevalence and incidence is difficult due to symptom overlap, underdiagnosis, and misdiagnosis; this study specifically assessed these in Japan.
- The research utilized data from the Japan Medical Data Center, analyzing healthcare claims for over 6 million individuals to estimate point-prevalence as of December 31, 2019, and incidence from 2014-2019.
- Findings showed that narcolepsy had a prevalence of 37.5 per 100,000 and IH had a prevalence of 7.7 per 100,000, with both conditions most common in younger adults aged 20-29.
Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the FAERS database.
Front Pharmacol
November 2024
Department of Pharmacology, University of the Basque Country UPV/EHU, Leioa, Spain.
Article Synopsis
- The study investigates the safety of various medications for narcolepsy, a lifelong neurological disorder, using five years of data from the FDA Adverse Event Reporting System (FAERS) to analyze pharmacological treatments like pitolisant, sodium oxybate, solriamfetol, and modafinil.
- Data analysis revealed significant signals for adverse drug events (ADEs), especially psychiatric and nervous system-related issues, with sodium oxybate raising concerns about suicidal thoughts and respiratory problems, while other medications highlighted issues like drug inefficacy and pregnancy-related risks.
- Overall, findings suggest that adverse reactions align with existing product warnings, emphasizing the need for careful management and monitoring of narcolepsy treatments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!